AR036333A1 - Estructura en solucion de il-13, sitios activos de il-13, agentes de union para il-13 y metodos para disenar agentes de union para il-13 - Google Patents

Estructura en solucion de il-13, sitios activos de il-13, agentes de union para il-13 y metodos para disenar agentes de union para il-13

Info

Publication number
AR036333A1
AR036333A1 ARP020102167A ARP020102167A AR036333A1 AR 036333 A1 AR036333 A1 AR 036333A1 AR P020102167 A ARP020102167 A AR P020102167A AR P020102167 A ARP020102167 A AR P020102167A AR 036333 A1 AR036333 A1 AR 036333A1
Authority
AR
Argentina
Prior art keywords
amino acid
acid residues
include amino
solution
methods
Prior art date
Application number
ARP020102167A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR036333A1 publication Critical patent/AR036333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describe una estructura en solución tridimensional de la IL-13 humana. La estructura tridimensional de IL-13 puede ser útil en el diseno y selección de agentes de unión para IL-13. En algunas realizaciones se describe una solución que contiene IL-13, en donde la IL-13 incluye los residuos de aminoácidos 1-113. La IL-13 puede ser no marcada, enriquecida en 15N o enriquecida en 15N, 13C. La IL-13 puede incluir cuatro hélices alfa: alfaA, alfaB, alfaC y alfaD, y dos cadenas beta, beta1, y beta2. La alfaA puede incluir los residuos de aminoácidos P6-Q22 de la IL-13, la beta1 puede incluir M33-W35 de la IL-13, la alfaB puede incluir los residuos de aminoácidos M43-I52 de la IL-13, la alfaC puede incluir los residuos de aminoácidos A59-F70 de la IL-13, la beta2 puede incluir los residuos de aminoácidos K89-E91 de la IL-13 y la alfaD puede incluir los residuos de aminoácidos V92-R108 de la IL-13. En ciertas realizaciones se describe un sitio activo de IL-13, donde el sitio activo está caracterizado por una estructura tridimensional que incluye las coordenadas estructurales relativas de los residuos de aminoácidos I52, Q64, R65 y M66 de la IL-13, +/- una desviación cuadrática media de los átomos conservados de la cadena principal de dichos aminoácidos no mayor que 1,5 Amstrong. También se describen métodos de uso de la estructura tridimensional de IL-13 para disenar y seleccionar agentes de unión para IL-13. Adicionalmente se describen agentes de unión para IL-13.
ARP020102167A 2001-06-07 2002-06-07 Estructura en solucion de il-13, sitios activos de il-13, agentes de union para il-13 y metodos para disenar agentes de union para il-13 AR036333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29660701P 2001-06-07 2001-06-07

Publications (1)

Publication Number Publication Date
AR036333A1 true AR036333A1 (es) 2004-09-01

Family

ID=23142750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102167A AR036333A1 (es) 2001-06-07 2002-06-07 Estructura en solucion de il-13, sitios activos de il-13, agentes de union para il-13 y metodos para disenar agentes de union para il-13

Country Status (9)

Country Link
US (1) US20030013851A1 (es)
EP (1) EP1402451A4 (es)
JP (1) JP2005506960A (es)
AR (1) AR036333A1 (es)
CA (1) CA2450147A1 (es)
IL (1) IL159215A0 (es)
MX (1) MXPA03011158A (es)
WO (1) WO2002101629A1 (es)
ZA (1) ZA200309894B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7774811B2 (en) * 2004-08-26 2010-08-10 Sony Corporation Method and system for use in displaying multimedia content and status
CA2587903A1 (en) * 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
ES2902063T3 (es) 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
WO2010021874A2 (en) 2008-08-20 2010-02-25 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
CN108277226A (zh) * 2018-02-01 2018-07-13 北京市华信行生物科技有限公司 白细胞介素-6的编码基因及其制备方法和应用
MX2020014027A (es) 2018-06-25 2021-03-09 Univ Washington Dise?o de novo de mimeticos de interleucina potentes y selectivos.
WO2020106708A1 (en) * 2018-11-20 2020-05-28 University Of Washington Split interleukin mimetics and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
CA2142860A1 (en) * 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
US5856116A (en) * 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
JP2001069995A (ja) * 1999-07-02 2001-03-21 Japan Tobacco Inc 結晶構造解析に適したｈｃｖポリメラーゼ及びその利用方法
US6795776B1 (en) * 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
EP1232253A2 (en) * 1999-11-16 2002-08-21 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a caspase-7
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME

Also Published As

Publication number Publication date
JP2005506960A (ja) 2005-03-10
WO2002101629A1 (en) 2002-12-19
MXPA03011158A (es) 2004-02-27
EP1402451A1 (en) 2004-03-31
ZA200309894B (en) 2004-09-29
CA2450147A1 (en) 2002-12-19
IL159215A0 (en) 2004-06-01
EP1402451A4 (en) 2005-01-05
US20030013851A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
AR036333A1 (es) Estructura en solucion de il-13, sitios activos de il-13, agentes de union para il-13 y metodos para disenar agentes de union para il-13
EP0684982B1 (en) Cleansing compositions
IT1288290B1 (it) Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
BR9506452A (pt) Composto heterocíclico processo de preparação do composto heterocíclico composição farmacêutica composição farmacêutica adequada para o tratamento de inflamação neurogênica processo de tratamento de inflamação neurogênica em um individuo necessitado de tal tratamento e uso de um composto heterocíclico
HK1062140A1 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical 4-n-(1,2-2-?)
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
EA199801001A1 (ru) Состав для очистки кожи, способы его приготовления и использования
ES2146784T3 (es) Composiciones de peracido espesadas.
ES2108375T3 (es) Derivados de oxazolidinadiona, su produccion y utilizacion para reducir los niveles de azucares y lipidos en sangre.
ES2026844T3 (es) Una composicion detergente.
MXPA05008382A (es) Acidos grasos, gliceridos y analogos con longitud de cadena media como estimuladores de eritropoyesis.
DE3586935D1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
EA200101116A1 (ru) Способ лечения фиброза с помощью альфа-4-субъединицы антагониста интегрина
AR043918A1 (es) Reduccion del crecimiento del vello utilizando una composicion que contiene difluorometilornitina
AR001838A1 (es) Derivados de azacicloal canos utiles para el tratamiento de la obesidad diabetes e hiperglucemia procedimiento para prepararlos composiciones farmacéuticas que los contienen y aplicación de dichos derivados en la preparación de dichas composiciones
PA8581701A1 (es) Derivados de indolilo
ATE205489T1 (de) N-substituierte azaheterocyclische carbonsäuren und ihre alkylester
ATE439846T1 (de) Zusammensetzungen von cholesterolsulfat und aminozuckern zur verbesserung der stratum corneum funktion
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
AR008371A1 (es) Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
JPS5756420A (en) Bath agent
RU2001126403A (ru) Низкомолекулярные производные пептидов как ингибиторы взаимодействия ламинина/нидогена
ES2970630T3 (es) Composiciones que comprenden unos compuestos organo-silanoles, y aplicaciones
BR0109343A (pt) Processo para produzir camptotecina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal